---
document_datetime: 2023-09-21 17:41:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/trizivir-epar-procedural-steps-taken-authorisation_en.pdf
document_name: trizivir-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.627046
conversion_datetime: 2025-12-26 17:36:18.992213
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The Applicant Glaxo Group Limited submitted on 17 December 1999 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Trizivir film-coated tablets, through the centralised procedure. After agreement by the CPMP on 23 September 1999,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

| Rapporteur:   | Dr. D. Brasseur   | Co-Rapporteur:   | Dr. E. Abadie   |
|---------------|-------------------|------------------|-----------------|

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## Scientific advice:

The Applicant did not seek scientific advice at the CPMP

## 2. Steps taken for the assessment of the product

- The procedure started on 21 January 2000.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  31  March 2000.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 10 April.
- The Rapporteur circulated a List of Questions to all CPMP members and the Applicant on the 8 May 2000.
- The Applicant submitted the responses to the List of Questions on 11 May 2000.
- The (Co) rapporteur's joint assessment report was circulated on the 18 May 2000.
- The  Co-Rapporteur's  assessment  report  of  study  CNAAB3005  was  circulated  to  all  CPMP members on the 15 June 2000.
- During  the  CPMP  meeting  on  27  June  2000,  outstanding  issues  were  addressed  by  the Applicant during an oral explanation before the CPMP. The list of outstanding issues can be found in Annex 6.
- During the meeting on 27-29 June 2000 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Trizivir on 29 June 2000.
- On 10 August Glaxo Group Ltd. submitted a valid application for an Urgent Safety Restriction (USR) for Ziagen (abacavir). This USR provided new information on hypersensitivity reactions involving an interruption of therapy for any reason. The USR for Ziagen was implemented on the 11 August.
- On  the  29  August  2000 the  European  Commission  informed  the  EMEA  that  the  decision making  process  for  Trizivir  had  been  suspended  and  asked  the  CPMP  to  evaluate  the consequences for Trizivir of the USR made for Ziagen (abacavir) during the September CPMP meeting in order to provide the Commission with an updated opinion.
- During  the  meeting  on  19-21  September  2000  the  CPMP,  in  the  light  of  the  overall  data submitted,  the  oral  explanation  by  the  applicant  in  front  of  the  CPMP,  and  the  scientific discussion  within  the  Committee,  issued  a  revised  positive  opinion  for  granting  a  Marketing Authorisation to Trizivir on 21 September  2000.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 28 December 2000.

1/1                                                                                   EMEA 2005